Author Instructions: Difference between revisions
No edit summary |
No edit summary |
||
| (10 intermediate revisions by the same user not shown) | |||
| Line 10: | Line 10: | ||
#Disease category overview pages (for example see [[Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms]], which are summaries of a group of diseases with links to all other relevant content. | #Disease category overview pages (for example see [[Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms]], which are summaries of a group of diseases with links to all other relevant content. | ||
#Disease-specific pages (for example see any links on the AML page), which is for individual disease entities and much more detailed. | #Disease-specific pages (for example see any links on the AML page), which is for individual disease entities and much more detailed. | ||
#Gene-specific pages (for example see [[ABL1]]) | #Gene-specific pages (for example see [[ABL1]]). For additional related instructions see '''[https://ccga.io/index.php/How_to_Curate_a_Gene_Page ''How to Curate a Gene Page'']'''. | ||
*For more details on how you use the site to be an author, please see an instructional video (see section below). Of note, we highly encourage authors to populate all the tables (i.e. for immunophenotype, chromosomal rearrangements, genomic gain/loss/LOH, etc) when applicable. | *For more details on how you use the site to be an author, please see an instructional video (see section below). Of note, we highly encourage authors to populate all the tables (i.e. for immunophenotype, chromosomal rearrangements, genomic gain/loss/LOH, etc) when applicable. | ||
| Line 21: | Line 21: | ||
*Trainees are highly encouraged and welcome to participate in this effort. Trainees are asked to work with a mentor to help review their page content before completion. | *Trainees are highly encouraged and welcome to participate in this effort. Trainees are asked to work with a mentor to help review their page content before completion. | ||
*For any additional questions, please | *For any additional questions, please '''[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]'''. If applicable, please include the disease category you are interested in working on in the subject line (''i.e.'' ALL, mature B-cell neoplasms, etc). | ||
*For technical issues, please '''[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]''' and include the title of the page on which the error occurred, a screenshot of the error message, the web browser you were using (i.e. firefox, google chrome, internet explorer, etc) and any other pertinent information. | |||
==Video Tutorial== | ==Video Tutorial== | ||
| Line 30: | Line 31: | ||
==Word Version Templates== | ==Word Version Templates== | ||
*For a Word document template for authoring a <u>disease-specific page</u> before transferring content online please see [[File:Disease or Entity-Specific Template Word Version (7-5-20).docx|left|thumb]]. | *For a Word document template for authoring a <u>'''disease-specific page'''</u> before transferring content online please see [[File:Disease or Entity-Specific Template Word Version (7-5-20).docx|left|thumb]]. | ||
*For a Word document template for authoring an <u>overview page</u> before transferring content online, please see [[File:Disease Overview Template Word Version (7-5-20).docx|none|thumb|Disease Overview Template]]. | *For a Word document template for authoring an <u>'''overview page'''</u> before transferring content online, please see [[File:Disease Overview Template Word Version (7-5-20).docx|none|thumb|Disease Overview Template]]. | ||
*For a Word document template for authoring a <u>gene-specific page</u> before transferring content online please see [[File:Gene-Specific Template Word Version (8-2-20).docx|left|thumb]]. | *For a Word document template for authoring a <u>'''gene-specific page'''</u> before transferring content online please see [[File:Gene-Specific Template Word Version (8-2-20).docx|left|thumb]]. | ||
*Please do use the provided tables if applicable. | *Please do use the provided tables if applicable. | ||
| Line 48: | Line 49: | ||
*<u>Citation for a CCGA page on an Author's CV</u>: | *<u>Citation for a CCGA page on an Author's CV</u>: | ||
#Naeini Y, Quintero-Rivera F. “Myeloid Sarcoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), created 2018 | #Naeini Y, Quintero-Rivera F. “Myeloid Sarcoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), created 06/23/2018, <nowiki>https://www.ccga.io/index.php/Myeloid_Sarcoma</nowiki>. | ||
*<u>Citation in Reports or Other Media</u>: | *<u>Citation in Reports or Other Media</u>: | ||
#Naeini Y, Quintero-Rivera F. “Myeloid Sarcoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated 2020 | #Naeini Y, Quintero-Rivera F. “Myeloid Sarcoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated 01/02/2020, <nowiki>https://www.ccga.io/index.php/Myeloid_Sarcoma</nowiki>. | ||